Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Lipella Pharmaceuticals Inc LIPO

Healthcare Biotechnology
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Its lead product candidates include LP-10, LP-310 and LP-410. LP-10 is the development name of its reformulation of tacrolimus specifically optimized for topical... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:LIPO)

Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus

GlobeNewswire 11 days ago

Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group

GlobeNewswire November 21, 2024

Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform

GlobeNewswire November 12, 2024

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split

GlobeNewswire November 1, 2024

Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference

GlobeNewswire October 29, 2024

Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform

GlobeNewswire October 15, 2024

Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit

GlobeNewswire October 9, 2024

Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus

GlobeNewswire September 24, 2024

Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York

GlobeNewswire August 27, 2024
View More News ››

Opinion & Analysis (NDAQ:LIPO)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:LIPO)

Lipella Pharmaceuticals Inc. (NASDAQ:LIPO): Reformulating Ge

http://beyondspx.com/2024/08/02/lipella-pharmaceuticals-inc-nasdaqlipo-reformulating-generic-drugs-for-new-applications/
MikeTester - August 3, 2024

RE:LIPO.....3 mins til opening bell

Live and learn Chasers!!!!!!!!!!!!!!!!!!
Iseneschal - July 31, 2024

LIPO....N.L.O.D...now at $0.9255

How do u like me so far ?????
Iseneschal - July 29, 2024

LIPO....sub $1 now

say goodnight sweet sharlet
Iseneschal - July 29, 2024

LIPO...Halt #2.....locked at $1

should resume in 2 mins I will say it now..... You've all been had.....AGAIN !!!!!
Iseneschal - July 29, 2024

LIPO....N.L.O.D

$1.08
Iseneschal - July 29, 2024
View more Bullboard ››

K9 Gold Corp

K9 Gold Corp

K9 Gold Corp. is engaged in the business of identification, acquisition and exploration of mineral interests. The Company’s ...
View More »